Cystic fibrosis (CF) is the most common lethal pediatric genetic disease in the Caucasian population. CF is caused by mutations in the CF gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-regulated chloride channel that belongs to the ATP-binding cassette family. A large number of mutations, including the most common deletion of phenylalanine 508 (deltaF508), cause folding and processing defect of CFTR. Using a functional high-throughput screening (HTS) assay, we have identified four classes of small molecules ('correctors') that partially revert the processing defect in transfected non-polarized and polarized cells, as well as in primary cultures of human airway epithelia. Our long-term goal is to identify clinically useful small molecules for CF therapy. Toward this goal we have three specific aims. 1) A comprehensive cell biological and biochemical analysis will establish the molecular mechanisms of deltaF508-CFTR corrector action. Potential sites of action to be analyzed include: translation, posttranslational folding, chaperone interactions, ER stability, cell surface stability, internalization and recycling efficiency and ubiquitination at the ER and post-Golgi compartments. Understanding the corrector mechanism is important to prioritize small molecule classes for further clinical development and in selecting synergistic combinations. 2) Additional HTS assays will be performed using a collection of >100,000 drug-like small molecules with maximum chemical diversity to identify highly efficient correctors. Hits will be optimized by medicinal chemistry and validated by biochemical and electrophysiological assays. A series of secondary and tertiary screens will be subsequently carried out to prioritize potential lead compounds for further development: efficacy studies on primary and immortalized cultures of human airway epithelia, pharmacological and efficacy analysis in rodents. 3) To identify novel targets for small molecule discovery, functional genetics for correction of the deltaF508-CFTR processing defect will be perfromed. Genome-wide loss-of-function (LOF) screens by siRNA knock-down and gain-of function (GOF) screens by cDNA transduction will be carried out using the biochemical/functional HTS assays. The proposed studies will provide an understanding of the small molecule correctors mechanism, as well as provide new classes of lead compounds for development and novel targets for small-molecule discovery in CF.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK075302-05
Application #
7907580
Study Section
Special Emphasis Panel (ZRG1-BST-L (50))
Program Officer
Mckeon, Catherine T
Project Start
2006-08-15
Project End
2011-09-26
Budget Start
2010-07-01
Budget End
2011-09-26
Support Year
5
Fiscal Year
2010
Total Cost
$208,573
Indirect Cost
Name
Mcgill University
Department
Type
DUNS #
205667090
City
Montreal
State
PQ
Country
Canada
Zip Code
H3 0-G4
Veit, Guido; Xu, Haijin; Dreano, Elise et al. (2018) Structure-guided combination therapy to potently improve the function of mutant CFTRs. Nat Med 24:1732-1742
Phuan, Puay-Wah; Veit, Guido; Tan, Joseph-Anthony et al. (2018) ?F508-CFTR Modulator Screen Based on Cell Surface Targeting of a Chimeric Nucleotide Binding Domain 1 Reporter. SLAS Discov 23:823-831
Bagdany, Miklos; Veit, Guido; Fukuda, Ryosuke et al. (2017) Chaperones rescue the energetic landscape of mutant CFTR at single molecule and in cell. Nat Commun 8:398
Avramescu, Radu G; Kai, Yukari; Xu, Haijin et al. (2017) Mutation-specific downregulation of CFTR2 variants by gating potentiators. Hum Mol Genet 26:4873-4885
Truong, Eric C; Phuan, Puay W; Reggi, Amanda L et al. (2017) Substituted 2-Acylaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A (TMEM16A). J Med Chem 60:4626-4635
Premchandar, Aiswarya; Kupniewska, Anna; Bonna, Arkadiusz et al. (2017) New insights into interactions between the nucleotide-binding domain of CFTR and keratin 8. Protein Sci 26:343-354
Haggie, Peter M; Phuan, Puay-Wah; Tan, Joseph-Anthony et al. (2017) Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product. J Biol Chem 292:771-785
Son, Jung-Ho; Zhu, Jie S; Phuan, Puay-Wah et al. (2017) High-Potency Phenylquinoxalinone Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activators. J Med Chem 60:2401-2410
Veit, Gudio; Avramescu, Radu G; Chiang, Annette N et al. (2016) From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell 27:424-33
Schnúr, Andrea; Hegyi, Péter; Rousseau, Simon et al. (2016) Epithelial Anion Transport as Modulator of Chemokine Signaling. Mediators Inflamm 2016:7596531

Showing the most recent 10 out of 32 publications